InvestorsHub Logo
Followers 130
Posts 14996
Boards Moderated 1
Alias Born 06/04/2018

Re: None

Thursday, 06/27/2019 10:40:30 AM

Thursday, June 27, 2019 10:40:30 AM

Post# of 3308
News: $ATOS Atossa Genetics' Preliminary Phase 2 Study Achieves Primary Endpoint: Topical Endoxifen Rapidly Reduces Breast Density

SEATTLE, June 27, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (Nasdaq: ATOS ), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that a preliminary analysis from its recently com...

Find out more https://marketwirenews.com/news-releases/atossa-genetics-preliminary-phase-2-study-achieves-primary-endp-8423746.html
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ATOS News